Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Outcomes of Plasma Cell Leukemia Patients in the Era of Next-Generation Novel Agents: A Single-Center Retrospective Cohort Study

Alex Ge, Chiung-Yu Huang, PhD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Nina Shah, MD, Sandy W. Wong, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141525

Published: 2020

Journal Articles

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Ying Sheng, Chiung-Yu Huang, PhD, Sophia Byslma, BS, Kelsey Natsuhara, MD, Dhruba Biswas, Mimi Lo, PharmD, BCPS, BCOP, Weiyun Z. Ai, Lawrence D Kaplan, MD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Nina Shah, MD, Charalambos Andreadis, MD MSCE, Sandy W. Wong, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-138940

Published: 2020

Journal Articles

Patterns of Tocilizumab Use Among Myeloma Patients Receiving Bcma-Directed Therapies: Effect on Day 30 Outcomes

Jeffrey Marsal, BS, Rahul Banerjee, MD, Chiung-Yu Huang, PhD, Mimi Lo, PharmD, BCPS, BCOP, Vanessa E Kennedy, MD, Shagun Arora, MD, Jeffrey L. Wolf, MD, Thomas Martin, III, MD, Sandy W. Wong, MD, Nina Shah, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-138618

Published: 2020

Journal Articles

Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex

Swetha Kambhampati, MD, Sandy W. Wong, MD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Priya Choudhry, PhD, William Karlon, MD PhD, Arun P. Wiita, MD PhD, Nina Shah, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-138869

Published: 2020

Journal Articles

Macrophage Activation Syndrome-like Manifestations (MAS-L) Following BCMA-Directed CAR T-Cells in Multiple Myeloma

Vanessa E Kennedy, MD, Christopher Wong, Chiung-Yu Huang, PhD, Jeffrey L. Wolf, MD, Thomas Martin, MD, Nina Shah, MD, Sandy W. Wong, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-142612

Published: 2020

Journal Articles

Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma

Joaquin Martinez Lopez, Rafael Alonso Fernández, Sandy W. Wong, MD, Rafael Rios, MD PhD, Nina Shah, MD, Maria Teresa Cedena Romero, MD PhD, Yanira Ruiz-Heredia, Jose M. Sanchez, MD, Santiago Barrio Garcia, PhD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-140352

Published: 2020

Journal Articles

Digital Life Coaching for Myeloma Patients Undergoing Transplantation

Rahul Banerjee, MD, Ann Lazar, PhD MS, Lisa Dunn, RN, Jennifer Knoche, RN, Kelly Jean Brassil, PhD MA, MSN, RN, Dhiren Patel, PharmD, Lindsey Jackson, MPH, CPH, Mimi Lo, PharmD, BCPS, BCOP, Anand Dhruva, MD, Shagun Arora, MD, Sandy W. Wong, MD, Jeffrey L. Wolf, MD, Thomas Martin, III, MD, Nina Shah, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-134163

Published: 2020

Journal Articles

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Ian Ferguson, BA, Yu-Hsiu T. Lin, BA, Sami Tuomivaara, PhD, Jeffrey L. Wolf, MD, Thomas G. Martin, III, MD, Sandy W. Wong, MD, Nina D. Shah, MD, Christoph Driessen, MD, Brian G. Van Ness, PhD, Arun P. Wiita, MD PhD

Blood (2019) 134 (Supplement_1): 1803.

https://doi.org/10.1182/blood-2019-131681

Published: 2019

Journal Articles

Next-Generation Sequencing Based Minimal Residual Disease Assessment in Peripheral Blood RNA from Multiple Myeloma Patients

Jeffrey L. Wolf, MD, Katherine A. Kong, PhD, Jenai Wilmoth, RN, Joshua Bayes, Amy Marsala, ANP,MPH, Victoria Carlton, PhD, Aaron Logan, MDPhD, Thomas G. Martin, III, MD

Blood (2016) 128 (22): 3286.

https://doi.org/10.1182/blood.V128.22.3286.3286

Published: 2016

Journal Articles

CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate

Daniel W. Sherbenou, MD PhD, Blake T. Aftab, PhD, Yang Su, PhD, Christopher R. Behrens, PhD, Arun P. Wiita, MD PhD, Aaron C. Logan, MD PhD, Diego Acosta-Alvear, PhD, Byron C. Hann, MD PhD, Peter Walter, PhD, Xiaobo Wu, MD, John P. Atkinson, MD, Jeffrey L. Wolf, MD, Thomas G. Martin, III, MD, Bin Liu, PhD

Blood (2016) 128 (22): 384.

https://doi.org/10.1182/blood.V128.22.384.384

Published: 2016

Journal Articles

Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the Mmrf CoMMpass Study

Blood (2016) 128 (22): 194.

https://doi.org/10.1182/blood.V128.22.194.194

Published: 2016

Journal Articles

Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma

Thomas G. Martin, III, MD, Gabriel N Mannis, Ajai Chari, MD, Pamela Munster, MD, Frank Campana, MD, Ai-Min Hui, MD PhD, Jeffrey L. Wolf, MD

Blood (2016) 128 (22): 2111.

https://doi.org/10.1182/blood.V128.22.2111.2111

Published: 2016

Journal Articles

Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Commpass Study

Blood (2015) 126 (23): 722.

https://doi.org/10.1182/blood.V126.23.722.722

Published: 2015

Journal Articles

Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk Following Autologous Hematopoietic Cell Transplantation

Gabriel N. Mannis, MD, Thomas G. Martin, III, MD, Lloyd E. Damon, MD, Charalambos Andreadis, MD MSCE, Rebecca L. Olin, MD MSCE, Katie Kong, Malek Faham, MD PhD, Weiyun Z. Ai, MD PhD, Karin ML Gaensler, MD, Peter H. Sayre, MD PhD, Jeffrey L. Wolf, MD PhD, Aaron C. Logan, MD PhD

Blood (2015) 126 (23): 1420.

https://doi.org/10.1182/blood.V126.23.1420.1420

Published: 2015

Journal Articles

Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma

Megan Murnane, M.Sc., Eugen Dhimolea, PhD, Ruojing Li, BS, Megan A. Bariteau, BSc, Diamond D. Wheeler, BS, Rosemary J. Akhurst, PhD, Aaron C. Logan, MD PhD, Pamela Munster, MD, Arun Wiita, MD PhD, Thomas G. Martin, III, MD, Jeffrey L. Wolf, MD PhD, Jun O. Liu, PhD, Constantine S. Mitsiades, MD PhD, Blake T. Aftab, PhD

Blood (2015) 126 (23): 503.

https://doi.org/10.1182/blood.V126.23.503.503

Published: 2015

Journal Articles

KIR and HLA Genotypes Influence Clinical Outcome in Multiple Myeloma Patients Treated with SAR650984 (Anti-CD38) in Combination with Lenalidomide and Dexamethasone

John Marra, BS, Juan Du, MD PhD, Jimmy Hwang, PhD, Jeffrey L Wolf, MD, Thomas G. Martin, MD, Jeffrey M Venstrom, MD

Blood (2014) 124 (21): 2126.

https://doi.org/10.1182/blood.V124.21.2126.2126

Published: 2014

Journal Articles

Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

Rachid Baz, MD, Thomas G. Martin, MD, Melissa Alsina, MD, Kenneth H. Shain, MD PhD, Hearn J. Cho, MD PhD, Jeffrey L Wolf, MD, Anuj Mahindra, MD, Ajai Chari, MD, Daniel M Sullivan, MD, Lisa A Nardelli, BS, CCRP, Kenneth Lau, BA, Xiuhua Zhao, Hui-Yi Lin, PhD, Sundar Jagannath, MD

Blood (2014) 124 (21): 303.

https://doi.org/10.1182/blood.V124.21.303.303

Published: 2014

Journal Articles

Pomalidomide (Pom) Dexamethasone (D) With Or Without Oral Weekly Cyclophosphamide (Cy) For Lenalidomide Refractory Multiple Myeloma (LRMM): A Multicenter Randomized Phase II Trial

Rachid Baz, MD, Thomas G Martin, III, MD, Melissa Alsina, MD, Kenneth H. Shain, MD, PhD, Hearn J. Cho, MD, PhD, Jeffrey L Wolf, MD, Anuj Mahindra, M.D., Ajai Chari, MD, Daniel Sullivan, M.D., Lisa A Nardelli, BS, CCRP, Kenneth Lau, BA, Hui-Yi Lin, PhD, Sundar Jagannath, MD

Blood (2013) 122 (21): 3200.

https://doi.org/10.1182/blood.V122.21.3200.3200

Published: 2013

Journal Articles

The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma

Beverly Harrison, Kenneth C. Anderson, MD, Noopur Raje, MD, Paul Richardson, MD, Diane Warren, Ajai Chari, MD, Sundar Jagannath, MD, Lisa La, Jesus Berdeja, MD, Meredith Zimlich, Joseph W. Fay, MD, Sheila Powell, RN, Craig C Hofmeister, MD, Nita Williams, BS, Andrzej J. Jakubowiak, MD, PhD, Todd M. Zimmerman, MD, Kathryn McDonnell, Amrita Y. Krishnan, MD, Lupe Duarte, CCRC, Shaji K Kumar, MD, Ann Birgin, CRA, Sagar Lonial, M.D., Kenisha Baron, Thomas Martin, MD, Jeffrey L Wolf, MD, Geraldine Pelle-Day, Ph.D., Glenna Auerback, Gregory Orloff, MD, Nikki Hodge, Donna E Reece, MD, FRCPC, Suzanne Trudel, MD, Engin Gul, HonBSc, Vivek Roy, M.D., Michele Maharaj, RN, David S. Siegel, MD, PhD, Adolfo Aleman, A. Keith Stewart, Rachel Hagerty, Moshe Talpaz, MD, Roxane Collins, Ravi Vij, MD, Mark A. Fiala, BS, CCRP, Jeffrey Zonder, M.D., Silva Pregja, Sharon Goldberg, Joan Levy, PhD, Karen Dietz, Walter Capone, Daniel Auclair, PhD, Anne Quinn Young, Kathy Giusti, MBA

Blood (2013) 122 (21): 5388.

https://doi.org/10.1182/blood.V122.21.5388.5388

Published: 2013

Journal Articles

Detection of Multiple Myeloma Cells in Peripheral Blood Using High-Throughput Sequencing Assay

Amitabha Mazumder, M.D., Malek Faham, MD, PhD, Mark Fiala, BS, CCRP, Mark Klinger, PhD, Thomas Martin, MD, Jeesun Park, B.A., Ravi Vij, MD, Jeffrey L Wolf, MD

Blood (2012) 120 (21): 321.

https://doi.org/10.1182/blood.V120.21.321.321

Published: 2012

NARROW

Outcomes of Plasma Cell Leukemia Patients in the Era of Next-Generation Novel Agents: A Single-Center Retrospective Cohort Study

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Patterns of Tocilizumab Use Among Myeloma Patients Receiving Bcma-Directed Therapies: Effect on Day 30 Outcomes

Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex

Macrophage Activation Syndrome-like Manifestations (MAS-L) Following BCMA-Directed CAR T-Cells in Multiple Myeloma

Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma

Digital Life Coaching for Myeloma Patients Undergoing Transplantation

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Next-Generation Sequencing Based Minimal Residual Disease Assessment in Peripheral Blood RNA from Multiple Myeloma Patients

CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate

Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the Mmrf CoMMpass Study

Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma

Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Commpass Study

Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk Following Autologous Hematopoietic Cell Transplantation

Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma

KIR and HLA Genotypes Influence Clinical Outcome in Multiple Myeloma Patients Treated with SAR650984 (Anti-CD38) in Combination with Lenalidomide and Dexamethasone

Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

Pomalidomide (Pom) Dexamethasone (D) With Or Without Oral Weekly Cyclophosphamide (Cy) For Lenalidomide Refractory Multiple Myeloma (LRMM): A Multicenter Randomized Phase II Trial

The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma

Detection of Multiple Myeloma Cells in Peripheral Blood Using High-Throughput Sequencing Assay

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only